4:05 PM
 | 
Feb 01, 2017
 |  BC Extra  |  Company News

Biogen hematology spinout Bioverativ launches

Biogen Inc. (NASDAQ:BIIB) spun out its hematology business into Bioverativ Inc. (NASDAQ:BIVV) as a standalone public company. Bioverativ's two marketed drugs, Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B, generated a combined $888 million in 2016 revenues.

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >